News & Press

Eiger BioPharmaceuticals: FDA Approval of Zokinvy™ (Ionafarnib)

December 8, 2020
News > CordenPharma congratulates Eiger BioPharmaceuticals on their recent FDA Approval of Zokinvy (lonafarnib).

CordenPharma congratulates Eiger BioPharmaceuticals on their recent FDA Approval of Zokinvy™ (lonafarnib): The First Treatment for Progeria Syndrome and Processing-Deficient Progeroid Laminopathies.


CordenPharma Colorado (Boulder, US) is honored to supply the Active Pharmaceutical Ingredient (API) in Zokinvy™ to support this disease-modifying agent that has demonstrated a statistically significant survival benefit in children and young adults with Hutchinson-Gilford Progeria Syndrome. Read Eiger’s full press release here.

CordenPharma congratulates Eiger BioPharmaceuticals on their recent FDA Approval of Zokinvy

CordenPharma congratulates Eiger BioPharmaceuticals on their recent FDA Approval of Zokinvy (lonafarnib): The First Treatment for Progeria Syndrome and Processing-Deficient Progeroid Laminopathies.